Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 60 years old
- People who have ovarian cancer that has been confirmed through laboratory testing of tissue samples (histopathology)
- People whose ovarian cancer has come back or spread to other parts of the body
- People whose ovarian cancer has been assessed as needing chemotherapy treatment
- People with a general health and activity level score of 1 or lower on a standard medical scale (meaning able to carry out light activity) (confirm with trial site)
- People whose doctors estimate they are likely to live for more than 3 months
- Women who are either pre-menopausal, or who have been post-menopausal for at least 12 months, and who have a negative pregnancy test
- People who agree to use effective contraception throughout the study and for 6 months after treatment ends
- People who are willing to sign a consent form and are able to attend all required study visits and follow-up appointments
- People whose bone marrow is healthy enough to allow stem cells to be collected from their body
Who may not be able to join:
- People who have a disease affecting the bone marrow
- People whose cancer has spread to the brain, spinal cord lining, bones, or bone marrow, as confirmed by scans or tissue testing
- People with serious heart failure
- People who have previously had a stem cell transplant or organ transplant from another person
- People who have active bleeding or a condition that causes the immune system to attack blood platelets
- People for whom chemotherapy is considered medically unsuitable
- People who test positive for HIV
- People who have an active hepatitis B or hepatitis C infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Dongling Zou, M.D., Chongqing University Cancer Hospital
Phone: 13657690699
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Grade 3-4 neutropenia; Time to reconstruct haematopoietic function; Incidence of febrile neutropenia (FN)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.